We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+10.46%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$235M
AUM Growth
+$15.3M
Cap. Flow
+$7.44M
Cap. Flow %
3.16%
Top 10 Hldgs %
31.26%
Holding
99
New
22
Increased
25
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$6.47M
2
CNC icon
Centene
CNC
+$4.68M
3
SYK icon
Stryker
SYK
+$4.47M
4
AET
Aetna Inc
AET
+$4.31M
5
GSK icon
GSK
GSK
+$4.18M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$7.97M
2
ABBV icon
AbbVie
ABBV
+$5.99M
3
A icon
Agilent Technologies
A
+$3.59M
4
PFE icon
Pfizer
PFE
+$2.77M
5
ELGX
Endologix Inc
ELGX
+$2.66M

Sector Composition

Rank Sector Weight
1 Healthcare 62.78%
2 Financials 4.02%
3 Industrials 1.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
76
AbbVie
ABBV
$438B
– –
-104,875
Closed -$5.99M
ACAD icon
77
CALL
Acadia Pharmaceuticals
ACAD
$5.06B
– –
-100,000
Closed -$2.8M
ALGN icon
78
PUT
Align Technology
ALGN
$12.5B
– –
-30,000
Closed -$2.18M
ANGO icon
79
CALL
AngioDynamics
ANGO
$651M
– –
-100,000
Closed -$1.23M
ARAY icon
80
Accuray
ARAY
$34.9M
– –
-441,300
Closed -$2.55M
BIIB icon
81
Biogen
BIIB
$30.6B
– –
-7,500
Closed -$1.95M
EWA icon
82
CALL
iShares MSCI Australia ETF
EWA
$1.47B
– –
-75,000
Closed -$1.45M
FOLD
83
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-100,000
Closed -$845K
LAB icon
84
Standard BioTools
LAB
$310M
– –
-125,000
Closed -$1.01M
OCUL icon
85
Ocular Therapeutix
OCUL
$2.03B
– –
-6,000
Closed -$58K
SPY icon
86
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$810B
– –
-20,000
Closed -$4.11M
SPY icon
87
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
– –
-10,000
Closed -$2.06M
SRPT icon
88
PUT
Sarepta Therapeutics
SRPT
$1.81B
– –
-100,000
Closed -$1.95M
TFX icon
89
Teleflex
TFX
$5.89B
– –
-15,000
Closed -$2.35M
TFX icon
90
PUT
Teleflex
TFX
$5.89B
– –
-15,000
Closed -$2.35M
VNDA icon
91
Vanda Pharmaceuticals
VNDA
$304M
– –
-67,500
Closed -$564K
VTRS icon
92
Viatris
VTRS
$18.7B
– –
-44,000
Closed -$2.04M
SCPX
93
DELISTED
Scorpius Holdings, Inc.
SCPX
– –
-1
Closed -$167K
CBAY
94
DELISTED
Cymabay Therapeutics
CBAY
– –
-56,000
Closed -$76K
NUVA
95
CALL
DELISTED
NuVasive, Inc.
NUVA
– –
-120,000
Closed -$5.84M
NXTM
96
CALL
DELISTED
NxStage Medical Inc.
NXTM
– –
-50,000
Closed -$750K
SGNT
97
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
– –
-89,713
Closed -$1.09M
HTWR
98
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
– –
-50,000
Closed -$1.57M
CPXX
99
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
– –
-55,000
Closed -$607K
1 2 3
4

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return

Pura Vida Investments's Q2 2016 Portfolio in Review

As of Q2 2016, Pura Vida Investments held 99 positions worth $235M, up 7% from $220M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Pura Vida Investments deployed $7.44M of net new capital in Q2 2016, opening 22 new positions and adding to 25 existing holdings. Its largest new stake was Medtronic: 80,000 shares worth $6.94M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 60% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Allergan plc, an estimated $7.97M trimmed.

  • Pura Vida Investments's largest Q2 2016 buy was Medtronic: 80,000 shares worth $6.94M.
  • Pura Vida Investments added most to Centene in Q2 2016, an estimated $4.68M increase.
  • Pura Vida Investments's biggest Q2 2016 reduction was Allergan plc, cutting an estimated $7.97M.
  • Pura Vida Investments fully exited AbbVie in Q2 2016, selling an estimated $5.99M.
  • Pura Vida Investments's ten largest holdings make up 31% of its $235M portfolio in Q2 2016.
  • Pura Vida Investments opened 22 new positions and closed 25 in Q2 2016.
  • Pura Vida Investments's portfolio value rose 7% quarter-over-quarter to $235M.

Based on Pura Vida Investments's 13F filing for Q2 2016, filed 15 Aug 2016.